表皮生长因子受体/间变性淋巴瘤激酶酪氨酸激酶抑制剂（EGFR/ALK-TKIs）与免疫检查点抑制剂（ICIs）在非小细胞肺癌单药治疗、联合治疗及序贯治疗中的最新进展
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.
作者信息
Liao Dehua, Yu Lun, Shangguan Dangang, Zhang Yongchang, Xiao Bowen, Liu Ni, Yang Nong
机构信息
Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Department of PET-CT Center, Chenzhou NO. 1 People's Hospital, Chenzhou, China.
出版信息
Front Pharmacol. 2022 Jun 6;13:905947. doi: 10.3389/fphar.2022.905947. eCollection 2022.
Abstract
Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases. Fortunately, the development of molecular oncology provides a promising and effective therapeutic strategy for lung cancers, including specific gene mutations/translocations and immune checkpoints, with epidermal growth factor receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later as the targeted therapy and immune checkpoint inhibitors (ICIs) as immunotherapy. This review summarized the recent therapy advancements of TKIs and ICIs in NSCLC and focused on the clinical effect of combination or sequential treatment so as to provide the effective advice for the treatment of NSCLC.
摘要
肺癌是癌症相关死亡的主要原因，发病率和死亡率都很高。非小细胞肺癌（NSCLC）是最常见的肺癌类型，占所有病例的85%。幸运的是，分子肿瘤学的发展为肺癌提供了一种有前景且有效的治疗策略，包括特定的基因突变/易位和免疫检查点，首先是表皮生长因子受体（EGFR）常见突变，随后是间变性淋巴瘤激酶（ALK）易位作为靶向治疗，以及免疫检查点抑制剂（ICI）作为免疫治疗。本综述总结了NSCLC中酪氨酸激酶抑制剂（TKI）和ICI的最新治疗进展，并重点关注联合或序贯治疗的临床效果，以便为NSCLC的治疗提供有效的建议。
相似文献
1
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer.表皮生长因子受体/间变性淋巴瘤激酶酪氨酸激酶抑制剂（EGFR/ALK-TKIs）与免疫检查点抑制剂（ICIs）在非小细胞肺癌单药治疗、联合治疗及序贯治疗中的最新进展
Front Pharmacol. 2022 Jun 6;13:905947. doi: 10.3389/fphar.2022.905947. eCollection 2022.
2
The safety profile of EGFR/ALK-TKIs administered immediately before or after ICIs in advanced NSCLC.在晚期 NSCLC 中，在接受 ICIs 之前或之后立即给予的 EGFR/ALK-TKIs 的安全性概况。
Int Immunopharmacol. 2023 Mar;116:109787. doi: 10.1016/j.intimp.2023.109787. Epub 2023 Feb 10.
3
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的分子机制和靶向治疗包括免疫疗法。
Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559.
4
Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.TP53 并发突变对晚期非小细胞肺癌 EGFR-TKIs 和 ALK-TKIs 靶向治疗的预后价值：一项荟萃分析。
BMC Cancer. 2020 Apr 16;20(1):328. doi: 10.1186/s12885-020-06805-5.
5
The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.吸烟状况对接受分子靶向治疗或免疫治疗与化疗的非小细胞肺癌患者无进展生存期的影响：一项荟萃分析。
J Clin Pharm Ther. 2021 Apr;46(2):256-266. doi: 10.1111/jcpt.13309. Epub 2020 Nov 5.
6
Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC).表皮生长因子受体（EGFR）通路、Yes 相关蛋白（YAP）与非小细胞肺癌（NSCLC）中程序性死亡配体 1（PD-L1）的调控。
Int J Mol Sci. 2019 Aug 5;20(15):3821. doi: 10.3390/ijms20153821.
7
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench.免疫检查点抑制剂在表皮生长因子受体（EGFR）突变的非小细胞肺癌中的应用：从临床到实验室研究
Ther Adv Med Oncol. 2020 Jun 9;12:1758835920930333. doi: 10.1177/1758835920930333. eCollection 2020.
8
Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer.ALK 阳性非小细胞肺癌患者的免疫治疗模式和结局。
Clin Lung Cancer. 2021 Jan;22(1):49-57. doi: 10.1016/j.cllc.2020.08.003. Epub 2020 Sep 18.
9
Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.表皮生长因子受体和间变性淋巴瘤激酶抑制剂治疗的非小细胞肺癌患者甲状腺功能障碍：一项前瞻性队列研究结果。
Lung Cancer. 2021 Jan;151:16-19. doi: 10.1016/j.lungcan.2020.11.007. Epub 2020 Nov 18.
10
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).优化表皮生长因子受体（EGFR）突变阳性非小细胞肺癌（NSCLC）中酪氨酸激酶抑制剂（TKI）的治疗顺序。
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
引用本文的文献
1
Prognostic role and functional impact of cadherin genes in non-small cell lung cancer tumorigenesis: mechanistic insights from and analyses.钙黏蛋白基因在非小细胞肺癌肿瘤发生中的预后作用和功能影响：来自[具体研究]和[具体分析]的机制见解
PeerJ. 2025 Aug 19;13:e19785. doi: 10.7717/peerj.19785. eCollection 2025.
2
Sequential versus massively parallel strategies for molecular characterization of non-small cell lung cancer samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration.通过支气管内超声引导经支气管针吸活检获取的非小细胞肺癌样本分子特征分析的序贯策略与大规模平行策略
J Bras Pneumol. 2025 Aug 18;51(4):e20250039. doi: 10.36416/1806-3756/e20250039. eCollection 2025.
3
Dynamic Alteration of HALP Score as a Predictor in Patients with Receiving Immunotherapy for Advanced Non-Small Cell Lung Cancer.HALP评分作为晚期非小细胞肺癌免疫治疗患者预测指标的动态变化
Medicina (Kaunas). 2025 May 27;61(6):989. doi: 10.3390/medicina61060989.
4
Contrast Clearance Analysis (CCA) to Assess Viable Tumour following Stereotactic Radiosurgery (SRS) to Brain Metastasis in Non-Small Cell Lung Cancer (NSCLC).对比剂清除分析（CCA）用于评估非小细胞肺癌（NSCLC）脑转移立体定向放射外科治疗（SRS）后存活肿瘤。
Cancers (Basel). 2024 Mar 20;16(6):1218. doi: 10.3390/cancers16061218.
5
PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer.源自肿瘤驯化血小板的PD-L1 mRNA作为非小细胞肺癌潜在的免疫治疗生物标志物
Transl Lung Cancer Res. 2024 Feb 29;13(2):345-354. doi: 10.21037/tlcr-24-29. Epub 2024 Feb 28.
6
Pan-immune-inflammation and its dynamics: predictors of survival and immune-related adverse events in patients with advanced NSCLC receiving immunotherapy.泛免疫炎症及其动态：接受免疫治疗的晚期 NSCLC 患者的生存和免疫相关不良事件的预测因子。
BMC Cancer. 2023 Oct 6;23(1):944. doi: 10.1186/s12885-023-11366-4.
7
Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer.迈向新一代 EGFR 抑制剂：非小细胞肺癌中 EGFR 突变介导的奥希替尼耐药概述。
Cell Commun Signal. 2023 Apr 11;21(1):71. doi: 10.1186/s12964-023-01082-8.
本文引用的文献
1
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.卡瑞利珠单抗联合卡铂和紫杉醇一线治疗晚期鳞状 NSCLC（CameL-Sq）：一项 3 期试验。
J Thorac Oncol. 2022 Apr;17(4):544-557. doi: 10.1016/j.jtho.2021.11.018. Epub 2021 Dec 16.
2
TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations.TPX-0131，一种强效的中枢神经系统穿透性、下一代野生型 ALK 和 ALK 耐药突变体抑制剂。
Mol Cancer Ther. 2021 Sep;20(9):1499-1507. doi: 10.1158/1535-7163.MCT-21-0221. Epub 2021 Jun 22.
3
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial.替雷利珠单抗联合化疗一线治疗局部晚期或转移性非鳞状 NSCLC（RATIONALE 304）：一项随机、III 期临床试验。
J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23.
4
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.替雷利珠单抗联合化疗与单纯化疗一线治疗晚期鳞状非小细胞肺癌的随机 3 期临床试验。
JAMA Oncol. 2021 May 1;7(5):709-717. doi: 10.1001/jamaoncol.2021.0366.
5
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020：全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
6
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial.卡瑞利珠单抗联合卡铂和培美曲塞对比单纯化疗用于未经化疗的晚期非鳞状非小细胞肺癌患者（CameL）：一项随机、开放标签、多中心、III 期临床试验。
Lancet Respir Med. 2021 Mar;9(3):305-314. doi: 10.1016/S2213-2600(20)30365-9. Epub 2020 Dec 18.
7
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).信迪利单抗联合培美曲塞和铂类化疗作为局部晚期或转移性非鳞状 NSCLC 患者一线治疗的有效性和安全性：一项随机、双盲、III 期研究（创新抗肿瘤 PD-1-11 研究）。
J Thorac Oncol. 2020 Oct;15(10):1636-1646. doi: 10.1016/j.jtho.2020.07.014. Epub 2020 Aug 8.
8
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.在 ALEX 研究中，未经治疗的晚期 ALK 阳性非小细胞肺癌患者的更新总生存和最终无进展生存数据。
Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11.
9
Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival.评估免疫检查点分子 PD-1、CTLA4、TIM-3 和 LAG-3 在不同癌症中的表达与治疗反应、肿瘤浸润免疫细胞和生存的关系。
Int J Cancer. 2020 Jul 15;147(2):423-439. doi: 10.1002/ijc.32785. Epub 2019 Dec 2.
10
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
Zotero 插件